Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of C2L-OCT-01 PR in acromegaly
2007-004320-21Phase 3Terminated
- Sponsor
- Ambrilia Biopharma Inc.
- Start
- Sep 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octreotide in acromegaly, sponsored by Ambrilia Biopharma Inc. Primary endpoints: Safety over additional 24 weeks and Biochemical control (GH and IGF-1). Started Sep 2007; status: terminated.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-004320-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004320-21.